hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

Intellectual property

International standards on intellectual property: click here

Get RSS feed of these results

Related stories and components

5 August 2010

AIDS Drugs Flow to the Third World

Author: Simeon Bennett and Tom Randall, Bloomberg Businessweek

Pharmaceutical companies, once blasted as uncaring or downright greedy for charging thousands of dollars for a year's worth of AIDS medicines like Viread in poor countries, lately have been slashing prices and licensing their drugs for free or nominal...

Read more

21 July 2010

[PDF] Business & human rights in South Asia – a round-up of recent developments

Author: Business & Human Rights Resource Centre

This briefing highlights reports from a range of sources about how businesses have impacted human rights, positively and negatively, in South Asia over the past year (mid-2009 to mid-2010)....

Read more

20 July 2010

AIDS Activists Launch United Nations Complaint on Impact of Obama Administration Trade Policies on Access to Medicines

Author: Jennifer Flynn, Health GAP [USA]

...AIDS activists from the U.S., Africa, Asia, and Latin America filed a complaint against the United States with the United Nations Special Rapporteur on the Right to Health. The complaint argues that the United States, working side by side with...

Read more

19 July 2010

AIDS Conference Campaigns For International Focus, Funding and Research

Author: Catherine Saez, Intellectual Property Watch

The 18th International AIDS conference opened...in Vienna on Sunday...The biennial conference...cover[s]...new drugs and therapies, universal access, the human rights dimension of the epidemic, including stigma and discrimination, but also the impact...

Read more

5 July 2010

[PDF] MICROSOFT/IDLO [Intl. Development Law Organization] Partnership for Access to New Technologies: a Key Challenge for developing Countries

Author: Intl Development Law Organization

[O]ften developing countries do not have the necessary financial means to carry out the required Research and development activities, indispensable to generate innovation. The only solution is to import technologies from abroad, which in turns entails...

Read more

1 July 2010
+ Français - Hide

Author: Alexandra Quinio, sur RSE et Pays Emergents & en Développement (RSE-et-PED.info)

Il s’agit......

Read more

21 May 2010

Haitian farmers reject Monsanto's seeds

Author: Beverly Bell, Latin American Bureau

…"A new earthquake" is what peasant farmer leader Chavannes Jean-Baptiste of the Peasant Movement of Papay (MPP) called the news that Monsanto will be donating 60,000 seed sacks (475 tons) of hybrid corn seeds and vegetable seeds, some of them treated...

Read more

Company response
27 April 2010

Novartis response to concerns raised by Doctors Without Borders regarding access to medicines in India

Author: Novartis

Read full response

31 March 2010

Transnational corporations and the duty to respect basic human rights

Author: Denis G. Arnold, University of North Carolina, Charlotte, in Business Ethics Quarterly

[T]he United Nations Special Representative on the issue of Human Rights and Transnational Corporations has emphasized a tripartite framework regarding business and human rights that includes the state “duty to protect,” the TNC “responsibility to...

Read more

10 February 2010

Court rejects Bayer's appeal [India]

Author: Rupali Mukherjee, Times of India

In a relief to generic companies and promoting consumers' access to affordable treatment, the Delhi high court dismissed an appeal by...Bayer Corporation, which sought patent linkage — linking regulatory approval of generic medicines with their patent...

Read more